Results of Interferon Alpha-2a Therapy in Patients with Behcet's Disease

Yalçındağ, F Nilüfer; Uzun, Aslıhan

doi:10.1089/jop.2011.0238

Cited by 32 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Open-label studies [Boyvat et al 2000;O'Duffy et al 1998;Georgiou et al 1998;Azizlerli et al 1996;Alpsoy et al 1994] Eye involvement Uncontrolled prospective study [Kotter et al 2003] Retrospective studies [Onal et al 2011;Sobaci et al 2010;Deuter et al 2010;Bodaghi et al 2007;Tugal-Tutkun et al 2006;Deuter et al 2004;Krause et al 2003;Calguneri et al 2003;Hamuryudan et al 2002;Wechsler et al 2000;Yalcindag and Uzun, 2012] Systematic review [Kotter et al 2004a] Mucocutaneous disease and arthritis Uncontrolled prospective study [Kotter et al 2004b] Systematic review [Kotter et al 2004a] Neuro-Behçet Case reports [Nichols et al 2001;Kuemmerle-Deschner et al 2008;…”

Section: ]mentioning

confidence: 99%

Update on the therapy of Behçet disease

Saleh

Arayssi

2014

Therapeutic Advances in Chronic Disease

116

101

View full text Add to dashboard Cite

Behçet disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. It manifests with oral and genital ulcerations, skin lesions, uveitis, and vascular, central nervous system and gastrointestinal involvement. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The cause of this disease is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. As the clinical expression of Behçet disease is heterogeneous, pharmacological therapy is variable and depends largely on the severity of the disease and organ involvement. Treatment of Behçet disease continues to be based largely on anecdotal case reports, case series, and a few randomized clinical trials.

show abstract

Section: ]mentioning

confidence: 99%

Update on the therapy of Behçet disease

Saleh

Arayssi

2014

Therapeutic Advances in Chronic Disease

116

101

View full text Add to dashboard Cite

show abstract

“…30 In other studies, the high efficacy of interferon-a-2a for BD with uveitis has also reported in Turkey and France. [31][32][33][34][35][36][37][38] A high incidence of ADRs is to be noted. Flu-like symptoms, including fever and/ or joint pain, occur in most of cases, but they appear only after first injection.…”

Section: Prednisolone (Predonine õ )mentioning

confidence: 99%

A Major Review: Current Aspects of Ocular Behçet's Disease in Japan

Namba

Gotô

Kaburaki

et al. 2015

Ocular Immunology and Inflammation

View full text Add to dashboard Cite

Diagnosis and treatment of Behçet's disease (BD) have continued to undergo new changes in recent years. We organized a Compilation Committee for Guidelines on Diagnosis and Treatment of Ocular Behçet's Disease with five ophthalmology research facilities in Japan (Hokkaido University, Health Sciences University of Hokkaido, University of Tokyo, Tokyo Medical University, and Yokohama City University), and accomplished the Major review of Current aspects of Ocular Behçet's Disease in Japan. The review consist of four chapters: introduction, ocular lesions, diagnosis, and treatment. We are very pleased if the guidelines are found to be effective and useful in improving the quality of life (QOL) and quality of vision (QOV) of BD patients in the world.

show abstract

“…Since its first use for the treatment of BD in the 1980s, a number of publications have reported on the beneficial effect of IFN- α , usually human recombinant IFN- α -2a, in recalcitrant forms of BU [170–178]. Although dose regimens varied, response rates (partial or complete) ranged between 78% and 98% with good functional outcomes and diminished uveitis attack frequencies.…”

Section: Immunologic Relevance Of Biologic Agents In Behçet's Uveitismentioning

confidence: 99%

Immunopathogenesis of Ocular Behçet’s Disease

Park

Kim

2014

Journal of Immunology Research

View full text Add to dashboard Cite

Behçet's disease (BD) is a chronic recurrent systemic inflammatory disorder of unknown etiology characterized by oral and genital ulcerations, skin lesions, and uveitis. The ocular involvement of BD, or Behçet's uveitis (BU), is characterized by panuveitis or posterior uveitis with occlusive retinal vasculitis and tends to be more recurrent and sight threatening than other endogenous autoimmune uveitides, despite aggressive immunosuppression. Although pathogenesis of BD is unclear, researches have revealed that immunological aberrations may be the cornerstone of BD development. General hypothesis of BD pathogenesis is that inflammatory response is initiated by infectious agents or autoantigens in patients with predisposing genetic factors and perpetuated by both innate and acquired immunity. In addition, a network of immune mediators plays a substantial role in the inflammatory cascade. Recently, we found that the immunopathogenesis of BU is distinct from other autoimmune uveitides regarding intraocular effector cell profiles, maturation markers of dendritic cells, and the cytokine/chemokine environment. In addition, accumulating evidence indicates the involvement of Th17 cells in BD and BU. Recent studies on genetics and biologics therapies in refractory BU also support the immunological association with the pathogenesis of BU. In this review, we provide an overview of novel findings regarding the immunopathogenesis of BU.

show abstract

Results of Interferon Alpha-2a Therapy in Patients with Behcet's Disease

Abstract: IFN-α-2a treatment is effective in Behcet uveitis refractory to traditional treatment regimens and provides significant improvement in visual prognosis.

Cited by 32 publications

References 17 publications

Update on the therapy of Behçet disease

Update on the therapy of Behçet disease

A Major Review: Current Aspects of Ocular Behçet's Disease in Japan

Immunopathogenesis of Ocular Behçet’s Disease

Contact Info

Product

Resources

About